Communiqués

25/01/23 CALITHERA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) AQ
09/01/23 CALITHERA BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) AQ
09/01/23 Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution AQ
15/11/22 Calithera: Q3 Earnings Snapshot AQ
14/11/22 CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
14/11/22 Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update AQ
08/11/22 Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 AQ
03/10/22 Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer AQ
29/09/22 CALITHERA BIOSCIENCES, INC. : Termination of a Material Definitive Agreement (form 8-K) AQ
29/09/22 Calithera Biosciences : Termination of Material Agreement - Form 8-K PU
06/09/22 Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference AQ
16/08/22 Calithera: Q2 Earnings Snapshot AQ
16/08/22 CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
15/08/22 Calithera Biosciences : Reports Second Quarter 2022 Financial Results and Recent Highlights - Form 8-K PU
15/08/22 Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights AQ
08/08/22 Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 AQ
14/07/22 Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences AQ
13/07/22 Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences AQ
06/07/22 Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer AQ
23/06/22 Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma AQ
14/06/22 CALITHERA BIOSCIENCES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) AQ
14/06/22 Calithera Biosciences Announces 1-for-20 Reverse Stock Split AQ
03/06/22 CALITHERA BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
23/05/22 CALITHERA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) AQ
18/05/22 Calithera Biosciences to Present at the H.C. Wainwright Global Investment Conference AQ
Aucun résultat pour cette recherche
-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT